Drug Data Exclusivity Push: Pharma Industry Faces Bitter Pill

Answer: A

Statement 1 is correct. Data exclusivity is precisely defined as a period where generic manufacturers cannot rely on the innovator's clinical trial data for their own regulatory approvals. Statement 2 is incorrect. Patent protection protects the underlying invention (the drug molecule or its formulation), while data exclusivity protects the *data* generated from clinical trials, preventing its reliance by others. They are distinct forms of protection. Statement 3 is incorrect. The TRIPS Agreement, specifically Article 39.3, requires WTO members to protect 'undisclosed test data' against unfair commercial use, but it does not explicitly mandate a fixed period of 'data exclusivity' as understood in many bilateral trade agreements. It offers flexibility to members in how they protect such data, allowing for public health considerations.

Answer: B

Statement 1 is correct. The primary concern of public health advocates is that data exclusivity would prevent generic manufacturers from using innovator data, thus delaying the entry of cheaper generic versions and extending the monopoly period of innovator drugs. Statement 2 is incorrect. While data exclusivity aims to incentivize R&D, its primary beneficiaries would be large multinational corporations or a few large Indian firms already engaged in novel drug discovery. It would likely disadvantage the majority of Indian generic manufacturers who rely on developing affordable copies, potentially stifling their business model rather than boosting their R&D in novel drugs. Statement 3 is incorrect. India's 'pharmacy of the world' status is largely built on its robust generic drug production. Implementing data exclusivity would likely undermine this status by making it harder for Indian companies to produce generics, thereby potentially weakening, not strengthening, this position. Statement 4 is correct. Delayed generic entry and extended monopolies would inevitably lead to higher drug prices, making essential medicines less affordable and accessible, especially in a country like India with a large population reliant on out-of-pocket healthcare expenditure.

Answer: C

Statement 1 is correct. Section 3(d) of the Indian Patent Act prevents the patenting of new forms of known substances unless they show significantly enhanced efficacy, effectively curbing 'evergreening' – the practice of extending patent terms by making minor modifications to existing drugs. This provision is crucial for promoting access to affordable generics. Statement 2 is incorrect. As explained in the previous question, TRIPS Article 39.3 requires protection for 'undisclosed test data' but does not explicitly mandate 'data exclusivity' with a fixed period. The interpretation and implementation of this article offer flexibility to member states. Statement 3 is correct. India has consistently opposed the implementation of data exclusivity, arguing that it would create a 'second layer' of protection beyond patents, further delaying generic entry and severely impacting the affordability and accessibility of medicines, which is a major public health concern in the country.